PRADAXA Drug Profile


Which patents cover Pradaxa, and what generic alternatives are available?


Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and eighty-seven patent family members in fifty-one countries.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.

Summary for PRADAXA 2018-01-23 09-52-09-433
Continue at:
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:

Leave a Reply

Your email address will not be published. Required fields are marked *